ARTICLE | Distillery Therapeutics
Therapeutics: Major histocompatibility complex class II (MHCII); glucose-6-phosphatase catalytic 2 (G6PC2; IGRP); proteolipid protein 1 (PLP1); myelin oligodend
March 10, 2016 8:00 AM UTC
Mouse studies suggest nanoparticles coated with MHCII molecules bound to disease-relevant peptides could help treat Type I diabetes, RA and MS. In a mouse model of Type I diabetes, nanoparticles coate...